1. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia;Quintas-Cardama;Cancer Control,2009
2. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy;Hochhaus;Leukemia,2002
3. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification;Gorre;Science,2001
4. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification;le Coutre;Blood,2000
5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Chronic Myelogenous Leukemia V.4.2013. © National Comprehensive Cancer Network, Inc 2013. All rights reserved. Accessed March 15, 2013. To view the most recent and complete version of the guideline, go online to www.nccn.org. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf.